

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS ✓
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Problem Image Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 6/00, A61L 27/00, 25/00 A61K 31/74	A1	(11) International Publication Number: WO 91/01126 (43) International Publication Date: 7 February 1991 (07.02.91)
(21) International Application Number: PCT/US90/03478 (22) International Filing Date: 20 June 1990 (20.06.90) (30) Priority data: 384,416 24 July 1989 (24.07.89) US (71) Applicant: ATRIX LABORATORIES, INC. [US/US]; 1625 Sharp Point Drive, Fort Collins, CO 80525 (US). (72) Inventors: DUNN, Richard, L. ; 451 Boardwalk Drive #501, Fort Collins, CO 80525 (US). TIPTON, Arthur, J. ; 412 Garfield, Fort Collins, CO 80524 (US). SOUTHARD, George, L. ; 1512 Brentwood Lane, Fort Collins, CO 80525 (US). ROGERS, Jack, A. ; 713 Greenfield Court, Fort Collins, CO 80524 (US).		(74) Agent: HAMRE, Curtis, B.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE*, DE (European patent)*, DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: BIODEGRADABLE SYSTEM FOR REGENERATING THE PERIODONTIUM (57) Abstract <p>Methods are described for assisting the restoration of periodontal tissue in a periodontal pocket and for retarding migration of epithelial cells along the root surface of a tooth. The methods involve placement of an in-situ forming biodegradable barrier adjacent the surface of a tooth. The barrier is microporous and includes pores of defined size. The barrier can include a biologically active agent.</p>		

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	PL	Poland
CA	Canada	JP	Japan	RO	Romania
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
DE	Germany	LU	Luxembourg	TD	Chad
DK	Denmark			TG	Togo
				US	United States of America

**BIODEGRADABLE SYSTEM
FOR REGENERATING THE PERIODONTIUM**

Background of the Invention

Periodontal disease is a highly prevalent
5 disease affecting 90% of the population. Surgery is one
of the primary courses of therapy. It assists the
patient in home management of the disease but does not
result in the restoration of lost periodontium. If
10 surgical therapy could be enhanced to restore the
periodontium the patient benefits of the procedure would
increase.

Successful periodontal restoration is known to
occur if periodontal ligament cells are allowed to
colonize root surfaces preferentially over gingival
15 epithelial cells, gingival fibroblasts or osteoblasts.
Several studies have been conducted which have
elucidated this fundamental mechanism and illustrated
its importance in obtaining successful periodontal
restoration.

20 It has been demonstrated that microporous
membranes applied beneath periodontal flaps during
surgery physically occlude epithelial cells from
apically migrating along the root surface. The
subsequent recolonization of the root surface by
25 gingival fibroblasts results in a more selective
population of the root surface by periodontal ligament
cells.

A number of membranes have been studied
including a Millipore® filter and a Teflon membrane.
30 The Teflon membrane is marketed under the trademark
GORE-TEX. A disadvantage of the Millipore® and GORE-
TEX® membranes is the need for a second surgical entry
to remove the membrane. Accordingly, a membrane for
periodontal restoration that is biodegradable in the
35 body would eliminate the need for a second surgical
entry and be beneficial to the patient and surgeon from
both cost and morbidity stand points.

The use of bioabsorbable membranes has been
reported. These include microfibrillar collagen, a

polygalactin (Vicryl) mesh, and a polylactic acid membrane. Results achieved with these biodegradable membranes as well as the Millipore® and GORE-TEX materials to induce guided tissue regeneration have been
5 variable. Precise cutting of membranes and placement over the treatment site can be difficult, time consuming and unpredictable in therapeutic outcome. Higher incidence of infection has also been reported with the nonbiodegradable membranes. The collagen membranes have
10 given variable degradation times in use and there is the concern for an immunological response to a foreign protein with this material.

There has not heretofore been provided a barrier membrane for tissue regeneration comprising a
15 totally synthetic biodegradable material that can be placed in the repair site to form a membrane having the precise geometry needed for that location and the optimum porosity to prevent epithelial tissue downgrowth.

20

Summary of the Invention

The present invention relates to the use of biodegradable polymers to promote guided tissue regeneration. These polymers can be uniquely
25 administered in liquid form, for example, with a syringe and needle, brush, or pressure applicator to a periodontal pocket or surgical site. When administered the liquid system coagulates or cures(sets) in a short time to form a solid or gelatinous implant. Before the
30 liquid system sets, the dental professional is able to manipulate the system to gain optimum conformity to the treatment site and overcome placement difficulties inherent in non-liquid systems.

The biodegradable liquid system is also
35 design d to generate a porous structure when coagulated or cured into the barrier membrane. In this respect, the membrane is similar to the Millipore® and GORE-TEX®

membranes which have been shown to work in humans. It is also similar to the Vicryl[®] mesh membrane except for the size of the pores. Based upon literature references and examination of the GORE-TEX[®] membrane, a minimum pore size of about 3 microns and a maximum pore size of approximately 500 microns is needed for an effective tissue barrier product. If the pore size is too small, the epithelial cells simply grow around the barrier; if the pores are too large, the epithelial cells grow through the membrane and fill the defect with the wrong type of tissue. But with the correct pore size, the cells grow into the structure to a certain point where they are prevented from growing through or around the barrier. The connective tissue cells also grow into the microporous membrane and block any tendency for downward migration of epithelial cells. In addition, the porous barrier permits the diffusion of essential nutrients and growth factors to the area being repaired.

The number of pores or the percent porosity of the membrane has also been found to be critical to the success of the barrier in regenerating new tissue. If only a few pores are present, the cells that grow into the membrane will be unable to prevent epithelial migration and invagination of the membrane. If there are too many pores, then the membrane will have little structural integrity and it will fracture in use. When this occurs, the membrane does not provide a barrier to cell migration. Consequently, the porous structure described in the present invention is essential to proper tissue regeneration and substantially different from the polylactic acid membranes described in the literature. The membrane-forming biodegradable liquid polymer system and the porous structure of the biodegradable polymer membrane represent a new and improved system over that of previous synthetic biodegradable polymer membranes for periodontal tissue regeneration.

WO 91/01120 PC1/US90/03478

The membran -forming liquid polymer systems are formulated from biodegradable polymers and copolymers comprising thermoplastic and thermosetting polymer systems. A thermoplastic system is provided in which a solid biodegradable polymer or copolymer is dissolved in a solvent, which is nontoxic and water miscible, to form a liquid solution. Once the polymer solution is placed into the body where there is sufficient water, the solvent dissipates or diffuses away from the polymer, leaving the polymer to coagulate or solidify into a solid structure which can serve as a barrier membrane. Alternatively, the liquid can be set outside of the body so that the dental professional can shape the material to fit the site of application. To obtain the porous structure needed for optimum barrier properties, water-soluble materials are incorporated into the polymer solution. These water-soluble materials may be solid particles such as sugar or salt crystals, polymers not soluble in the biodegradable polymer or its carrier solvent, or polymers that are also soluble in the solvent for the biodegradable polymer.

Biologically active agents can also be incorporated into the polymer to provide a porous structure as well as to produce a biological effect. For these systems, the biologically active agent is added to the polymer solution where it is either dissolved to form a homogenous solution or dispersed to form a suspension or dispersion of drug within the polymeric solution. When the polymer solution is exposed to body fluids or water, the solvent diffuses away from the polymer-drug mixture and water diffuses into the mixture where it coagulates the polymer thereby trapping or encapsulating the drug within the polymeric matrix as the implant solidifies. The release of the drug then follows the general rules for diffusion or dissolution of a drug from within the polymeric matrix. The dissolution of the biologically active agent creates

pores in the polymer membrane into which the cells can penetrate. The size of the pores generated is dependent upon the particle size of the drug or the water-soluble particle if the material is dispersed within the polymer matrix. If the drug or material is soluble in the polymer solution, then the quantity and the uniformity of the distribution of the material within the polymer matrix as the polymer coagulates will determine the size of the pores when the agent or material is released or dissolved out of the solid polymer matrix.

The other liquid polymer system which can be used to generate the barrier membrane in-situ is a thermosetting system comprising reactive, liquid, oligomeric polymers which contain no solvents and which cure in place to form solids, usually with the addition of a curing catalyst. The liquid oligomeric polymers useful in the thermosetting system are first synthesized via copolymerization of either DL-lactide or L-lactide with ϵ -caprolactone using a multifunctional polyol initiator and a catalyst to form polyol-terminated prepolymers. The polyol-terminated prepolymers are then converted to acrylic ester-terminated prepolymers, preferably by acylation of the alcohol terminus with acryloyl chloride via a Schotten-Baumann-like technique, i.e., reaction of acyl halides with alcohols. The acrylic ester-terminated prepolymers may also be synthesized in a number of other ways, including but not limited to, reaction of carboxylic acids, i.e., acrylic or methacrylic acid with alcohols, reaction of carboxylic acid esters i.e., methyl acrylate or methyl methacrylate with alcohols by transesterification, and reaction of isocyanatoalkyl acrylates i.e., isocyanatoethyl methacrylate with alcohols.

The liquid acrylic-terminated prepolymer is cured, preferably by the addition of benzoyl peroxide or azobisisobutyronitrile, to a more solid structure. Thus, for a barrier membrane utilizing these

crosslinkable polymers, the catalysts is added to the liquid acrylic-terminated prepolymer immediately prior to injection into the body. Once in the repair site, the crosslinking reaction will proceed until sufficient molecular weight has been obtained to cause the polymer to solidify and form the barrier membrane. The liquid prepolymer can also be formed and cured outside of the tissue repair site to give a membrane with the exact dimensions needed for that location. The thermosetting polymers may be made porous by the same techniques described above for the thermoplastic polymers. Water-soluble components such as sodium chloride, sodium carbonate, sugar, citric acid, and polymers such as poly(vinyl pyrrolidone) and poly(ethylene glycol) may be incorporated into the liquid prepolymer before it is cured. Biologically active agents that release or dissolve out of the solid polymer matrix may also be used to create a porous structure as well as a biological effect.

In both the thermoplastic and the thermosetting systems, the advantages of liquid application are achieved. For example, the polymer may be injected via syringe and needle into the periodontal pocket or surgical site while it is in liquid form and then left in-situ to form a solid, microporous, biodegradable barrier membrane or implant structure. Alternatively, the liquid system can be set outside of the body so it can be shaped or molded to a site. In addition to providing a porous barrier membrane, those liquid polymers containing biologically active agents may be used to stimulate or accelerate tissue repair by serving as a drug delivery vehicle also. As such, the liquid polymer may be injected directly into the area of tissue needing repair. The release of the active agents will stimulate cellular activity and the porous structure of the implant will allow tissue ingrowth and subsequent tissue repair as the polymer biodegrades.

The term "biologically active agent" means a drug or some other substance capable of producing a physiological effect on a body. Drugs suitable for the purpose of restoring the periodontium are of synthetic and natural origin. Such drugs are termed tissue repair mediators and include but are not limited to fibronectin (FN), endothelial cell growth factor (ECGF), cementum attachment extracts (CAE), ketanserin, human growth hormone (HGH), animal growth hormones, fibroblast growth factor (FGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF), interleukin-1 (IL-1), transforming growth factor (TGF β -2), insulin-like growth factor II (IGF-II), human alpha thrombin (HAT), osteoinductive factor (OIF), bone morphogenetic protein (BMP), and releasing factors for any of the above. The interaction of these biochemical mediators and cellular extracts with regenerative cells has been discussed in the literature. Other drugs such as antibiotics or antimicrobial agents can also be added to the liquid polymer to give membranes or implants which prevent an infection.

It is an object of the present invention to provide a method to aid in the restoration of the periodontium through guided tissue regeneration by physical barrier means.

It is also an object of the present invention to provide a method to aid in the restoration of the periodontium by serving as a controlled release delivery system for mediators that stimulate periodontal tissue repair.

It is also an object of the present invention to provide a method to assist in the restoration of the periodontium simultaneously through guided tissue regeneration by barrier means and the controlled release of mediators that stimulate periodontal tissue repair.

It is also an object of the present invention to provide an in-situ forming microporous implant to

serve as a physical barrier or delivery system for tissue repair mediators.

It is also an object of this invention to provide a method to prevent infection by the
5 incorporation of antimicrobial agents into the system while aiding in the restoration of the periodontium through physical barrier means and/or the delivery of tissue repair mediators.

10 Detailed Description of the Invention

The present invention relates to in-situ forming biodegradable microporous membranes or implants that can be used to aid in the restoration of the periodontium by the principal of guided tissue
15 regeneration and/or delivery of biochemical mediators to restore the periodontium. Two types of biodegradable polymers described for these purposes are thermoplastic polymers dissolved in a biocompatible solvent and thermosetting polymers that are liquids without the use
20 of solvents.

A. Thermoplastic System

A thermoplastic system is provided in which a solid, linear-chain, biodegradable polymer is dissolved
25 in a biocompatible solvent to form a liquid, which can then be administered via a syringe and needle. Examples of biodegradable polymers which can be used in this application are polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides,
30 polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid),
35 poly(amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of

the above materials. The preferred polymers are those which have lower degree of crystallization and are more hydrophobic. These polymers and copolymers are more soluble in the biocompatible solvents than the highly crystalline polymers such as polyglycolide and chitin which also have a high degree of hydrogen-bonding. Preferred materials with the desired solubility parameters are the polylactides, polycaprolactones, and copolymers of these with each other and glycolide in which there are more amorphous regions to enhance solubility.

It is also preferred that the solvent for the biodegradable polymer be non-toxic, water miscible, and otherwise biocompatible. Solvents that are toxic should not be used to inject any material into a living body. The solvents must also be biocompatible so that they do not cause severe tissue irritation or necrosis at the site of implantation. Furthermore, the solvent should be water miscible so that it will diffuse quickly into the body fluids and allow water to permeate into the polymer solution and cause it to coagulate or solidify. Examples of such solvents include N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, propylene glycol, acetone, methyl acetate, ethyl acetate, ethyl lactate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, dimethyl sulfone, tetrahydrofuran, caprolactam, decylmethyloxide, oleic acid, N,N-diethyl-m-toluamide, and 1-dodecylazacycloheptan-2-one. The preferred solvents are N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, and acetone because of their solvating ability and their compatibility.

The solubility of the biodegradable polymers in the various solvents will differ depending upon their crystallinity, their hydrophilicity, hydrogen-bonding, and molecular weight. Thus, not all of the biodegradable polymers will be soluble in the same solvent, but each polymer or copolymer should have its

optimum solvent. Lower molecular-weight polymers will normally dissolve more readily in the solvents than high-molecular-weight polymers. As a result, the concentration of a polymer dissolved in the various solvents will differ depending upon type of polymer and its molecular weight. Conversely, the higher molecular-weight polymers will normally tend to coagulate or solidify faster than the very low-molecular-weight polymers. Moreover the higher molecular-weight polymers will tend to give higher solution viscosities than the low-molecular-weight materials. Thus for optimum injection efficiency, the molecular weight and the concentration of the polymer in the solvent have to be controlled.

For polymers that tend to coagulate slowly, a solvent mixture can be used to increase the coagulation rate. Thus one liquid component of the mixture is a good solvent for the polymer, and the other component is a poorer solvent or a non-solvent. The two liquids are mixed at a ratio such that the polymer is still soluble but precipitates with the slightest physiological environment. By necessity, the solvent system must be miscible with both the polymer and water.

In one envisioned use of the thermoplastic system, the polymer solution is placed in a syringe and injected through a needle into the periodontal site. Once in place, the solvent dissipates, the remaining polymer solidifies, and a solid structure such as a membrane or implant is formed. The polymer will adhere to the surrounding tissue or bone by mechanical forces and can assume the shape of the periodontal pocket or surgical site. Unlike collagen implants, the degradation time of the polymer can be varied from a few weeks to years depending upon the polymer selected and its molecular weight. The injectable system can also be used to adhere gingival tissue to other tissue or other implants to tissue by virtue of its mechanical bonding.

Another envisioned use of the liquid polymer system is to provide a drug-delivery system. In this use, a bioactive agent is added to the polymer solution prior to injection, and then the polymer/solvent/agent mixture is injected into the body. In some cases, the drug will also be soluble in the solvent, and a homogeneous solution of polymer and drug will be available for injection. In other cases, the drug will not be soluble in the solvent, and a suspension or dispersion of the drug in the polymer solution will result. This suspension or dispersion can also be injected into the body. In either case, the solvent will dissipate and the polymer will solidify and entrap or encase the drug within the solid matrix. The release of drug from these solid implants will follow the same general rules for release of a drug from a monolithic polymeric device. The release of drug can be affected by the size and shape of the implant, the loading of drug within the implant, the permeability factors involving the drug and the particular polymer, the porosity of the polymer implant or membrane, and the degradation of the polymer. Depending upon the bioactive agent selected for delivery, the above parameters can be adjusted by one skilled in the art of drug delivery to give the desired rate and duration of release.

The term drug or bioactive (biologically active) agent as used herein includes without limitation physiologically or pharmacologically active substances that act locally or systemically at a periodontal site. Representative drugs and biologically active agents to be used with the syringeable, in-situ forming, solid microporous implant systems include, without limitation, FN, ECGF, CAE, ketanserin, HGH, animal growth hormones, FGF, PDGF, EGF, IL-1, TGF β -2, ILGF-II, HAT, OIF, BMP, and releasing factors for any of the above. Antimicrobial agents and antibiotics can also be used. To those skilled in the art, other drugs or biologically active

agents that can be released in an aqueous environment can be utilized in the described injectable delivery system. Also, various forms of the drugs or biologically active agents may be used. These include
5 without limitation forms such as uncharged molecules, molecular complexes, salts, ethers, esters, amides, etc., which are biologically activated when injected into the body.

The amount of drug or biologically active agent incorporated into the injectable, in-situ, solid forming implant depends upon the desired release profile, the concentration of drug required for a biological effect, and the length of time that the drug has to be released for treatment. There is no critical upper limit on the
15 amount of drug incorporated into the polymer solution except for that of an acceptable solution or dispersion viscosity. The lower limit of drug incorporated into the delivery system is dependent simply upon the activity of the drug and the length of time needed for
20 treatment.

Not only can the drug incorporated into the system be used to create a biological effect, but it can also be used to create the microporous structure needed for connective tissue ingrowth and barrier to epithelial migration. If the drug is highly water soluble, it will
25 be dissolved or released from the polymer matrix quickly and create the pores required for tissue ingrowth. If the drug is released or dissolved slowly, the pores can be created at a rate similar to that for cell migration into the newly formed pores. The size of the pores will
30 be dependent upon the size of the drug particles in the polymer matrix. If the drug is insoluble in the polymer formulation, then discrete particles of drug can be properly sized or sieved before incorporation into the
35 polymer solution to give the desired pore size. If the drug is also soluble in the polymer solution, then the distribution or mixing of the drug within the

formulation and the method by which the drug precipitates upon contact with water of body fluids will determine the pore sizes when the precipitated particles are later dissolved. The pore sizes can be determined by examining cross-sections of the coagulated polymer matrix with scanning electron microscopy. An average pore size and distribution can be calculated from these examinations. For an effective tissue barrier, the pore sizes should be a minimum of 3 microns and less than 500 microns. The preferred pore sizes should range from about 20 to 200 microns.

The number of pores or the percent porosity will depend upon the quantity of water-soluble drug or other water-soluble ingredients incorporated into the formulation. Larger quantities of such materials will provide more pores and a higher percent porosity. The percent porosity should be between 5% and 95% with the preferable range of 25 to 85% for optimum tissue ingrowth and structural integrity. The percent porosity can be determined by a number of different methods including mercury intrusion porosimetry, specific gravity or density comparisons, and calculations from scanning electron microscopy photographs. To simplify the determination of porosity in our system, we have defined percent porosity as the percent water-soluble material present in the formulation. This calculation is appropriate because the polymer forms a membrane as soon as it contacts body fluid or water and the dissolution of the water-soluble materials, including the solvent, creates pores. Thus, a formulation that contains 30% polymer and 70% solvent or other water-soluble material would provide a solid polymer matrix with 70% porosity.

Pores can also be created in the polymer matrix by the use of water-soluble compounds that are not drugs. Almost any biocompatible water-soluble material can be used. These materials can either be soluble in

the polymer solution or simply dispersed within the formulation. The same parameters described above for the drugs govern the pore size and percent porosity obtained with these nondrug materials. Thus, the size of the particles dispersed within the polymer formulation determine the size of the resulting pores in the solidified polymer matrix and the quantity of material determines the percent porosity. If the material is soluble in the polymer formulation, then the mixing or distribution of the material in the polymer solution and the aggregation when the polymer coagulates will determine the size of the resultant pores when the material dissolves out of the polymer matrix. A number of different water-soluble materials can be dispersed or dissolved in the polymer formulation to give pores when they are slowly dissolved in the body. These include sugars, salts, and polymers. Examples are sucrose, dextrose, sodium chloride, sodium carbonate, hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone.

In all cases, the microporous solid implant formed with the injectable polymer solution will slowly biodegrade within the periodontal site and allow natural tissue to grow and replace the implant as it disappears. Thus, when the material is injected into a soft-tissue defect, it will fill that defect and provide a scaffold for natural collagen tissue to grow. This collagen tissue will gradually replace the biodegradable polymer. With hard tissue such as bone, the biodegradable polymer will support the growth of new bone cells which will also gradually replace the degrading polymer. For drug-delivery systems, the solid microporous implant formed from the injectable system will release the drug contained within its matrix at a controlled rate until the drug is depleted. With certain drugs, the polymer will degrade after the drug has been completely released. With other drugs such as peptides or

proteins, the drug will be completely released only after the polymer has degraded to a point where the non-diffusing drug has been exposed to the body fluids.

5 B. Thermosetting System

The injectable, in-situ forming, biodegradable microporous implants can also be produced by crosslinking appropriately functionalized biodegradable polymers. The thermosetting system comprises reactive,
10 liquid, oligomeric polymers which cure in place to form solids, usually with the addition of curing catalyst. Although any of the biodegradable polymers previously described for the thermoplastic system can be used, the limiting criteria is that low-molecular-weight oligomers
15 of these polymers or copolymers must be liquids and they must have functional groups on the ends of the prepolymer which can be reacted with acryloyl chloride to produce acrylic-ester-capped prepolymers.

The preferred biodegradable system is that
20 produced from poly(DL-lactide-co-caprolactone), or "DL-PLC". Low-molecular-weight polymers or oligomers produced from these materials are flowable liquids at room temperature. Hydroxy-terminated PLC prepolymers may be synthesized via copolymerization of DL-lactide or
25 L-lactide and ϵ -caprolactone with a multifunctional polyol initiator and a catalyst. Catalysts useful for the preparation of these prepolymers are preferably basic or neutral ester-interchange (transesterification) catalysts. Metallic esters of carboxylic acids
30 containing up to 18 carbon atoms such as formic, acetic, lauric, stearic, and benzoic are normally used as such catalysts. Stannous octoate and stannous chloride are the preferred catalysts, both for reasons of FDA compliance and performance.

35 If a bifunctional polyester is desired, a bifunctional chain initiator such as ethylene glycol is employed. A trifunctional initiator such as

trimethylolpropane produces a trifunctional polymer, etc. The amount of chain initiator used determines the resultant molecular weight of the polymer or copolymer. At high concentrations of chain initiator, the
5 assumption is made that one bifunctional initiator molecule initiates only one polymer chain. On the other hand, when the concentration of bifunctional initiator is very low, each initiator molecule can initiate two polymer chains. In any case, the polymer chains are
10 terminated by hydroxyl groups. In this example, the assumption has been made that only one polymer chain is initiated per bifunctional initiator molecule. This assumption allows the calculation of theoretical molecular weight for the prepolymers.

15 The diol prepolymers are converted to acrylic-ester-capped prepolymers via a reaction with acryloyl chloride under Schotten-Baumann-like conditions. Other methods of converting the diol prepolymers to acrylic-ester-capped prepolymers may also be employed.

20 The acrylic prepolymers and diol prepolymers are then cured. The general procedure for the curing of the prepolymers is now described: to 5.0g of acrylic prepolymer contained in a small beaker is added a solution of benzoyl peroxide (BP) in approximately 1 mL
25 of CH_2Cl_2 . In some cases, fillers or additional acrylic monomers may be added to the prepolymers prior to the introduction of the BP solution. The mixtures are stirred thoroughly and then poured into small petri dishes where they are cured at room temperature in air
30 or in a preheated vacuum oven.

This thermosetting system may be used wherever a biodegradable implant is desired. For example, because the prepolymer remains a liquid for a short time after addition of the curing agent, the liquid
35 prepolymer/curing agent mixture may be placed into a syringe and injected into a body. The mixture then solidifies in-situ, thereby providing an implant without

an incision. The mixtur may also be placed into an incision with ut the use of a syringe to form a membrane or implant. Furthermore, a drug-delivery system may be provided by adding a biologically active agent to the prepolymer prior to injection. Once in-situ, the system will cure to a solid; eventually, it will biodegrade, and the agent will be gradually released. A microporous structurè may be formed by the dissolution or release of the biologically active agent, or water-soluble materials may be incorporated into the liquid prepolymer before it is injected into the body and cured. The same parameters described for the thermoplastic system also govern the size of the pores formed in the implant and the percent porosity.

Detailed Description of Examples

The following examples are set forth as representative of the present invention. These examples are not to be construed as limiting the scope of the invention as these and other equivalent embodiments will be apparent in view of the present disclosure, figures, and accompanying claims.

Example 1

A formulation consisting of a 5% equimolar mixture of sodium carbonate and citric acid, 34.8% poly(DL-lactide) (DL-PLA) and 60.2% N-methyl pyrrolidone (NMP) was prepared by suspending particles of the sodium carbonate and citric acid in the polymer solution. The DL-PLA polymer had a molecular weight of about 30,000 daltons (inherent viscosity of 0.38 dL/g). One drop of the formulation was precipitated into a vial containing phosphate-buffered saline (PBS) or water. The vial was placed in a 37°C shaker bath. After remaining at 37°C for a time period of at least 48h, the sample was removed from the fluid, and dried in vacuo prior to

examination by SEM. A porous structure resulted with 5 μ pores and a percent porosity of 65.2%.

Example 2

5 A formulation consisting of 5% sucrose, 34.8% DL-PLA and 60.2% NMP was treated as in Example 1. A porous structure resulted with a large number of 3 μ pores and a percent porosity of 65.2%.

Example 3

10 A formulation consisting of 5% poly(vinyl pyrrolidone)(PVP), 34.8% DL-PLA and 60.2% NMP was treated as in Example 1. A porous structure resulted with pore sizes of 5-10 μ and a percent porosity of
15 65.2%.

Example 4

A formulation consisting of 10% PVP, 33.0% DL-PLA and 57.0% NMP was treated as in Example 1. A porous
20 structure resulted with pore sizes of 5-20 μ and a percent porosity of 67.0%.

Example 5

A formulation was prepared consisting of 50%
25 DL-PLA and 50% NMP with two different molecular weights of polymer. A water-soluble low-molecular-weight DL-PLA with a molecular weight of 2000 daltons was mixed with a higher-molecular-weight DL-PLA with an inherent viscosity of 0.38 dL/g and an approximate molecular
30 weight of 30,000 daltons and dissolved NMP to give a solution with a composition of 38% low-molecular-weight DL-PLA, 12% higher molecular weight DL-PLA, and 50% NMP. This formulation was treated as described in Example 1
to give a porous structure with pores from 10-50 μ and a
35 percent porosity of 50%.

Example 6

5 A formulation consisting of 5% ethoxydihydro-sanguinarine (SaOEt), 27.5% DL-PLA and 67.5% NMP was treated as in Example 1. SaOEt is an antimicrobial agent derived from the benzophenanthridine alkaloids. A porous structure resulted with pore sizes of 15-30 μ and a percent porosity of 72.5%.

Example 7

10 A formulation consisting of 5% SaOEt, 27.5% DL-PLA and 67.5% NMP was treated as in Example 1. The difference was that the DL-PLA used in this sample had a lower molecular weight of about 10,000 daltons. A porous structure resulted with pore size of 4-8 μ . This sample was also examined by X-ray tomography on a wet sample. Scanned at intervals of 0.25 mm, the samples showed porosity throughout with a percent porosity of 72.5%.

Example 8

20 A formulation consisting of 5.0% sanguinarine chloride (SaCl), 47.5% DL-PLA and 47.5% NMP was placed in the periodontal pocket of a human. SaCl is an antimicrobial and anti-inflammatory agent derived from the benzophenanthridine alkaloids. After 28 days the samples was removed, dried in vacuo and examined by SEM. Small pores of 1-2 μ and larger pores of 10-20 μ were evident with a percent total porosity of 52.5%. Approximately 50% of the pores were 10-20 μ .

30

Example 9

35 A formulation consisting of 33% PVP, 33% 50/50 copolymer of DL-lactide and glycolide (DL-PLG) and 34% NMP was treated as in Example 1. A porous structure resulted with pore sizes of 3-10 μ . Further examination showed the pores in an interconnecting network with a percent porosity of 67%.

Example 10

A lypholized sampl of fibron ctin, a tissue growth and cell attachment factor, was added to a solution of DL-PLA in NMP to give a dispersion with 13.2% by weight of the lypholized fibronectin product, 30.4% DL-PLA, and 56.4% NMP. Because the fibronectin product contained various salts as a result of the lypholization process, there was only 0.89% of active drug in the formulation. This formulation was added to a phosphate-buffered receiving fluid where it coagulated into a solid mass. The receiving fluid was maintained at 37°C under agitation and changed often to prevent a high concentration of the drug in the fluid. The receiving fluid was analyzed for total protein concentration by the Pierce BCA protein assay and the cumulative percentage of drug released was calculated. After one day, about 12% of the drug was released with 25% after 2 days, 26% after 3 days, 28% after 4 days, 30% after 5 days, and 33% after 7 days. The percent porosity of the initial implant was 56.4% with the level increasing as the drug was released. The pores produced were greater than 3 μ .

Example 11

Ketanserin tartrate, a serotonin antagonist and wound-healing factor, was added to a solution of DL-PLA in NMP to give a clear solution containing 10% by weight ketanserin, 33% DL-PLA, and 57% NMP. When this formulation was added to phosphate-buffered saline solution (pH 7.1), it coagulated into a solid mass. The receiving fluid was maintained at 37°C under agitation and exchanged frequently. It was noted that as the ketanserin released from the polymer it precipitated in the buffered saline solution. The precipitated drug was filtered and dissolved in dim thylformamide for analysis by HPLC. The release of ketanserin was essentially

constant throughout the period of observation with about 0.8% after 1 day, 3.2% after 6 days, and 7.3% after 16 days. The percent porosity of the initial implant was 57% and the pore size was 5-15 μ . The percent porosity increased as the drug was released from the polymer matrix.

WHAT IS CLAIMED IS:

1. An in-situ forming biodegradable implant for assisting the restoration of periodontal tissue in a periodontal pocket, comprising:
a biodegradable polymer having a porosity in the range of 5 to 95%, wherein the porosity is provided by pores having a size in the range of about 3 to 500 microns.
2. A biodegradable implant according to claim 1, wherein the implant includes pores having a size in the range of about 20 to 200 microns.
3. A biodegradable implant according to claim 1, wherein the polymer is thermoplastic and dissolved in a water-miscible liquid solvent to form a solution, wherein when the solution is placed in the pocket, the polymer is capable of forming a solid implant in the pocket upon dissipation of the solvent.
4. A biodegradable implant according to claim 3, wherein the solution further comprises a water-soluble material.
5. A biodegradable implant according to claim 4, wherein the water-soluble material is selected from the group consisting of sugars, salts, and water-soluble polymers.
6. A biodegradable implant according to claim 4, wherein the water-soluble material is present in an amount of about 5 to 85 percent by weight based upon the total weight of the polymer.
7. A biodegradable implant according to claim 3, wherein the polymer is selected from the group

consisting of polylactides, polyglycolides,
polycaprolactones, polyanhydrides, polyamides,
polyurethanes, polyesteramides, polyorthoesters,
polydioxanones, polyacetals, polycarbonates,
5 polyorthocarbonates, polyphosphazenes, polyhydroxy-
butyrates, polyhydroxyvalerates, polyalkylene oxalates,
polyalkylene succinates, poly(malic acid), poly(amino
acids), polyvinylpyrrolidone, polyethylene glycol,
polyhydroxycellulose, chitin, chitosan, and copolymers,
10 terpolymers and any combinations thereof.

8. A biodegradable implant according to claim 3,
wherein the solvent is selected from the group
consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone,
15 ethanol, propylene glycol, acetone, ethyl acetate, ethyl
lactate, methyl acetate, methyl ethyl ketone, dimethyl-
formamide, dimethyl sulfoxide, dimethyl sulfone,
tetrahydrofuran, caprolactam, decylmethyloxide,
oleic acid, N,N-diethyl-m-toluidine, and 1-
20 dodecylazacycloheptan-2-one and any combination and
mixture thereof.

9. A biodegradable implant according to claim 1,
wherein the polymer is in a liquid state, capable of
25 thermosetting, and, when placed in the pockets is
capable of being cured in-situ to form the implant.

10. A biodegradable implant according to claim 9,
wherein the liquid polymer is an acrylic-ester-
30 terminated prepolymer which when combined with a curing
agent and placed in the pocket, is capable of being
cured in-situ.

11. A biodegradable implant according to claim 10,
35 wherein the prepolymer comprises poly(DL-lactide-co-
caprolactone).

12. A biodegradable implant according to claim 1, further comprising a biologically active agent.

13. An in-situ forming biodegradable barrier for
5 retarding apical migration of epithelial cells along the root surface of a tooth, comprising:

a biodegradable polymer having a porosity in the range of 5 to 95%, wherein the porosity is provided by pores having a size in the range of about 3 to 500
10 microns.

14. A biodegradable barrier according to claim 13, wherein the barrier includes pores having a size in the range of about 20 to 200 microns.

15

15. A biodegradable barrier according to claim 13, wherein the polymer is thermoplastic and dissolved in a water-miscible liquid solvent to form a solution, wherein when the solution is placed adjacent to the root
20 surface, the polymer is capable of forming a solid implant adjacent the root surface upon dissipation of the solvent.

16. A biodegradable barrier according to claim 15, wherein the solution further comprises a water-soluble material.

25

17. A biodegradable barrier according to claim 16, wherein the water-soluble material is selected from a group consisting of sugars, salts, and water-soluble
30 polymers.

18. A biodegradable barrier according to claim 16, wherein the water-soluble material is present in an amount of about 5 to 85% by weight based upon the total
35 weight of the polymer.

19. A biodegradable barrier according to claim 15, wherein the polymer is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, 5 polyesteramides, polyorthoesters, polydioxanones, polyacetals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), 10 polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymer, terpolymers and any combination and mixture thereof.

20. A biodegradable barrier according to claim 15, 15 wherein the solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, ethanol, propylene glycol, acetone, ethyl acetate, ethyl lactate, methyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, dimethyl sulfone, 20 tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid, N,N-diethyl-m-toluidine, and 1-dodecylazacycloheptan-2-one and combinations and mixtures thereof.

21. A biodegradable barrier according to claim 13, 25 wherein the polymer is in a liquid state, capable of thermosetting, and, when placed adjacent to the root surface, is capable of being cured in-situ to form the barrier.

22. A biodegradable barrier according to claim 21, 30 wherein the liquid polymer is an acrylic-ester-terminated prepolymer which when combined with a curing agent and placed adjacent to the root surface, is 35 capable of being cured in-situ.

23. A biodegradable barrier according to claim 22, wherein the polymer comprises poly(DL-lactide-co-caprolactone).

5 24. A biodegradable barrier according to claim 13, further comprising a biologically active agent.

10 25. An in-situ forming biodegradable implant for promoting guided tissue regeneration in a periodontal pocket, comprising:

 a biodegradable polymer having a porosity in the range of 5 to 95%, wherein the porosity is provided by pores having a size in the range of about 3 to 500 microns.

15 26. A biodegradable implant according to claim 25, wherein the implant includes pores having a size in the range of about 20 to 200 microns.

20 27. A biodegradable implant according to claim 25, wherein the polymer is thermoplastic and dissolved in a water-miscible liquid solvent to form a solution, wherein when the solution is placed in the pocket, the polymer is capable of forming a solid implant in the
25 pocket upon dissipation of the solvent.

 28. A biodegradable implant according to claim 27, wherein the solution further comprises a water-soluble material.

30 29. A biodegradable implant according to claim 28, wherein the water-soluble material is selected from the group consisting of sugars, salts, and water-soluble polymers.

35 30. A biodegradable implant according to claim 28, wherein the water-soluble material is present in an

amount of about 5 to 85 perc nt by weight based upon the weight of the polymer.

31. A biodegradable implant according to claim 27,
5 wherein the polymer is selected from the group
consisting of polylactides, polyglycolides, polycapro-
lactones, polyanhydrides, polyamides, polyurethanes,
polyesteramides, polyorthoesters, polydioxanones,
polyacetals, polycarbonates, polyorthocarbonates,
10 polyphosphazenes, polyhydroxybutyrates, polyhydroxy-
valerates, polyalkylene oxalates, polyalkylene
succinates, poly(malic acid), poly(amino acids),
polyvinylpyrrolidone, polyethylene glycol, polyhydroxy-
cellulose, chitin, chitosan, and copolymers, terpolymers
15 and any combination and any mixture thereof.

32. A biodegradable implant according to claim 27,
wherein the solvent is selected from the group
consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone,
20 ethanol, propylene glycol, acetone, ethyl acetate, ethyl
lactate, methyl acetate, methyl ethyl ketone, dimethyl-
formamide, dimethyl sulfoxide, dimethyl sulfone, tetra-
hydrofuran, caprolactam, decylmethylsulfoxide, oleic
acid, N,N-diethyl-m-toluamide, and 1-
25 dodecylazacycloheptan-2-one and any combination and any
mixture thereof.

33. A biodegradable implant according to claim 25,
wherein the polymer is in a liquid state, capable of
30 thermosetting, and, when placed in the pocket, is
capable of being cured in-situ to form said implant.

34. A biodegradable implant according to claim 33,
wherein the liquid polymer is an acrylic-ester-
35 terminated prepolymer which when combined with a curing
ag nt and placed in th pocket, is capable of being
cured in-situ.

35. A biodegradable implant according to claim 34, wherein the prepolymer comprises poly(DL-lactide-co-caprolactone).


5

36. A biodegradable implant according to claim 25, further comprising a biologically active agent.

INTERNATIONAL SEARCH REPORT

PCT/US 90/03478

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K6/00 ; A61L27/00 ; A61L25/00 ; A61K31/74		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61K ; A61L	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claims No. ¹³
X	EP,A,0297535 (VIPONT PHARMACEUTICAL) 04 January 1989 see page 3, lines 29 - 43; claims	1, 3, 7, 9, 11, 12, 25, 27, 31 33-36
A	EP,A,0271831 (DENTSPLY) 22 June 1988 see page 1, lines 10 - 16, 54 - 55	1, 7, 9, 10
A	WO,A,8901006 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 09 February 1989	
A	EP,A,0171173 (W.L. GORE & ASSOCIATES) 12 February 1986	
A,P	FR,A,2635685 (G.C. DENTAL) 02 March 1990	
<p>¹⁰ Special categories of cited documents : 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"T" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
09 OCTOBER 1990	30. 10. 90	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Mme N. KUIPER 	

Form PCT/ISA/210 (second sheet) (January 1985)

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US9003478
SA 38697**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 19/10/90

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0297535	04-01-89	AU-A- 1849988	05-01-89
		JP-A- 1085916	30-03-89
EP-A-0271831	22-06-88	US-A- 4846165	11-07-89
		AU-A- 8196387	23-06-88
WO-A-8901006	09-02-89	AU-A- 2301888	01-03-89
EP-A-0171173	12-02-86	AU-A- 2866489	03-08-89
		AU-A- 2866589	08-06-89
		AU-A- 2866689	08-06-89
		AU-A- 4139985	09-01-86
		AU-B- 582773	13-04-89
		AU-A- 4540385	10-02-86
		CA-A- 1255580	13-06-89
		CA-A- 1249459	31-01-89
		DE-A- 3565045	27-10-88
		EP-A- 0188546	30-07-86
		GB-A, B 2161080	08-01-86
		JP-A- 61122855	10-06-86
		JP-T- 61502866	11-12-86
		WO-A- 8600517	30-01-86
FR-A-2635685	02-03-90	JP-A- 2063465	02-03-90
		AU-A- 3949089	08-03-90
		DE-A- 3928933	01-03-90
		GB-A- 2223027	28-03-90
		SE-A- 8902867	01-03-90

EPO FORM P0079 For more details about this annex : see Official Journal of the European Patent Office, No. 12/82